Granules India Limited

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:51 31/05/2024 pm IST			5-day change	1st Jan Change
418.2 ^INR	-1.51%		-2.53%	+3.15%

15/05	Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024
15/05	Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue	MT

Granules India Limited Announces Resignation of Robert George Cunard, Independent Director

March 17, 2023 at 06:21 pm IST

Granules India Limited announced that Mr. Robert George Cunard Independent Director of the Company has vide resignation letter dated March 15, 2023, which was received by the Company on March 17, 2023, resigned from the Board of Directors of the Company with immediate effect, on account of personal reasons.

Latest news about Granules India Limited

Transcript : Granules India Limited, Q4 2024 Earnings Call, May 15, 2024	15/05
Granules India Posts Decline in Fiscal Q4 Consolidated Net Profit, Revenue	15/05	MT
Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion	15/05	RE
Granules India Limited Recommends Final Dividend for the Financial Year 2023-24, Payable on July 30, 2024	15/05	CI
Granules India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	15/05	CI
Granules India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	15/05	CI
Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares	30/04	MT
Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	15/04	MT
Granules India Unit Gets VAI Status for Virginia Facility	03/04	MT
Granules India Limited Announces Appointment of Directors	02/04	CI
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director	29/03	CI
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations	29/03	CI
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer	11/03	CI
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing	05/03	CI
Transcript : Granules India Limited, Q3 2024 Earnings Call, Jan 23, 2024	23/01
Paracetamol maker Granules India posts marginal rise in Q3 profit	23/01	RE
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit	23/01	MT
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	23/01	CI
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA	18/12	MT
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets	13/12	MT
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets	13/12	CI
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension	04/12	MT
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand	09/11	RE
Transcript : Granules India Limited, Q2 2024 Earnings Call, Nov 09, 2023	09/11
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI

Chart Granules India Limited

Duration

Period

More charts

Company Profile

Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Ex-dividend day for final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Granules India Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

418.2 INR

Average target price

473 INR

Spread / Average Target

+13.12%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GRANULES INDIA LIMITED	+3.15%	1.24B
ELI LILLY AND COMPANY	+40.73%	734B
NOVO NORDISK A/S	+32.83%	591B
JOHNSON & JOHNSON	-6.30%	350B
MERCK & CO., INC.	+15.15%	315B
ABBVIE INC.	+4.05%	276B
ASTRAZENECA PLC	+15.00%	238B
NOVARTIS AG	+9.78%	206B
ROCHE HOLDING AG	-5.52%	204B
AMGEN INC.	+6.17%	161B

Other Pharmaceuticals